Exchange Surveillance
No active ASM or GSM measures on this stock.
Price band ± 20%
Price
Trading Data
range barsReturns
absolute and vs benchmark indexAbout the Company
Jenburkt Pharmaceuticals Limited is an India-based company engaged pharmaceutical formulations. The Company is engaged in manufacturing and marketing of speciality and pharmaceutical formulations and healthcare products. The Company manufactures products in two types divsions: consumer divsion and pharmaceutical division. The Company`s products under consumer divsion include nocal tablets, nocal sachet, and nocal granular. The Company`s products uner the pharmaceutical division include anti-arthritic, anti-osteoporotic, antibiotics, anti-diabitic, neuropathy, anti-inflammory analgesics, gastro intenstinal, dermatologicals, aphrodisiac, anti-cough, cold and allergy, anti-ulcerants, and anti-malarial. The Company has approximately 50 brands, which are promoted through doctors.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- HQ
- Mumbai, Maharashtra
- Chairman
- Ashish U Bhuta
- CEO & MD
- Ashish U Bhuta
- Registrar
- Bigshare Services Pvt. Ltd.
- Exchange
- NSE
- ISIN
- INE354A01013
Institutional Demand
passive ownership through ETFsContext
where this company sitsFrequently Asked
▶What is the share price of Jenburkt Pharmaceuticals Ltd today?
Jenburkt Pharmaceuticals Ltd (JENBURPH) is trading at ₹870.95. The price shown is the latest available from the exchange feed and updates through the trading session.
▶What is JENBURPH’s P/E ratio versus the sector?
JENBURPH trades at a P/E of 11.4. Its industry median is shown alongside it in Key Stats, so you can see at a glance whether the stock is priced above or below the businesses it competes with. A lower P/E is not automatically cheaper — it can also reflect slower expected growth.
▶What is JENBURPH’s dividend yield?
JENBURPH has a dividend yield of 2.24%, based on dividends declared over the last twelve months against the current price. The full dividend history is on the News & Filings tab.
▶What is JENBURPH’s 52-week high and low?
JENBURPH has traded between ₹850 and ₹1,073.9 over the past year. The Trading Data block shows where the current price sits inside that band.
▶What is the market capitalisation of Jenburkt Pharmaceuticals Ltd?
Jenburkt Pharmaceuticals Ltd has a market capitalisation of ₹408 crore.
▶What is JENBURPH’s return on equity?
JENBURPH reports a return on equity of 20.2%. ROE measures profit generated per rupee of shareholder capital, and is most meaningful compared against others in Drug Manufacturers - Specialty & Generic.
▶Who are JENBURPH’s competitors?
The Peers block on this page lists other Drug Manufacturers - Specialty & Generic companies with their price, P/E and market capitalisation. The Valuation tab compares multiples against the industry median in more depth.
▶What is JENBURPH’s promoter holding?
Promoters hold 46.62% of JENBURPH. The Ownership tab shows the full shareholding pattern — promoter, FII, DII and public — and how each has moved across recent quarters.
▶Which indices include JENBURPH?
Index membership is listed in the Context block on this page, along with the weight JENBURPH carries in each. That weight is what determines how much passive money tracks the stock.
▶Is Jenburkt Pharmaceuticals Ltd a good buy?
We do not publish buy or sell calls. What this page gives you instead is the evidence: our Value & Investment Index for where the price sits against its own history, the Fundamental Strength Index for the quality of the business, an investment checklist of criteria applied to every stock, and pros and cons generated from JENBURPH’s own numbers. The judgement is yours.
JENBURPH at a glance
Jenburkt Pharmaceuticals Ltd operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector. Jenburkt Pharmaceuticals Ltd (JENBURPH) last traded at ₹870.95, giving it a market capitalisation of ₹408 crore. The 52-week range is ₹850 to ₹1,073.9, and the price is 9% of the way up that range. It trades at a price-to-earnings ratio of 11.4. Promoters hold 46.62% of the company in the latest shareholding filing.
| Market cap | ₹408 crore |
|---|---|
| P/E | 11.4 |
| ROE | 20.2% |
| ROCE | 27.0% |